Cara Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Cara Therapeutics, Inc.

Cara Therapeutics, Inc. was a U.S. biopharmaceutical company historically listed on the Nasdaq in the United States, before undergoing a major strategic transformation in 2025. Founded in 2004 and headquartered in Stamford, Connecticut, the company focused on developing novel medicines for pruritus, or severe itching associated with multiple disease states. Its scientific strategy centered on selectively targeting peripheral kappa opioid receptors, which differentiated its approach from more conventional symptom-management therapies. ([ir.caratherapeutics.com](https://ir.caratherapeutics.com/static-files/619cd29f-cdcc-4a47-be0b-ca3f3b7bb033?utm_source=openai)) From a business-history perspective, Cara spent much of its life as a research-driven biotech financed through equity offerings and partner agreements, before moving into commercialization with KORSUVA (difelikefalin) injection. The FDA approved KORSUVA in August 2021 for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, and the company stated that U.S. commercial launch began in April 2022. Cara also described ex-U.S. commercialization arrangements through partners including CSL Vifor, Maruishi, and CKDP across selected territories, which gave the franchise a broader international footprint than its small-cap scale might otherwise suggest. ([ir.caratherapeutics.com](https://ir.caratherapeutics.com/static-files/74ab5103-7736-46ce-81b7-654b5ed5bcb4?utm_source=openai)) The most important recent corporate event is the merger with Tvardi Therapeutics, announced in late 2024 and completed on April 15, 2025. At closing, Cara changed its corporate name to Tvardi Therapeutics, Inc., and its shares began trading on Nasdaq under the ticker TVRD after a 1-for-3 reverse stock split implemented in connection with the transaction. For equity investors, this is a critical point: any legacy analysis of Cara must be viewed through the post-merger structure, since the publicly traded company is no longer the same standalone asset profile it was before the deal. ([nasdaq.com](https://www.nasdaq.com/press-release/cara-therapeutics-announces-1-3-reverse-stock-split-connection-proposed-merger-tvardi?utm_source=openai)) Before the merger, Cara’s competitive position was that of a niche specialty-biotech player with a focused clinical and commercial franchise in pruritus, rather than a broad diversified pharma company. That specialization offered differentiation, but it also created concentration risk, because the investment case depended heavily on a small number of assets, clinical readouts, reimbursement dynamics, and partner execution. SEC filings and company materials highlight the usual biotech risks: financing needs, regulatory uncertainty, limited product breadth, and dependence on strategic partners. ([ir.caratherapeutics.com](https://ir.caratherapeutics.com/static-files/cfcc614c-3ff7-4142-bacb-70a45c565b1a?utm_source=openai)) For recent news, the key takeaway in 2025-2026 is the post-merger evolution into Tvardi, which shifted the company’s public-market identity away from Cara’s original pruritus platform toward Tvardi’s STAT3-focused fibrosis strategy. Investors tracking insider activity or Form 4 filings should therefore treat Cara as a legacy corporate shell that has materially changed through the merger, rather than as a continuing standalone commercial biotech. In short, Cara Therapeutics was a Nasdaq-listed U.S. biotech built around pruritus and kappa-opioid biology, but its most recent chapter is a transformational merger that redefined the company entirely. ([nasdaq.com](https://www.nasdaq.com/press-release/tvardi-therapeutics-announces-second-quarter-2025-results-and-provides-business?utm_source=openai))